Have any questions? 706-721-6582 or cts@augusta.edu
- VT3996-201: A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
Clinical Trial
VT3996-201: A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
The purpose of this study is to find a safe and tolerated dose of the combination of an investigational drug, called VRx-3996, along with an antiviral (fights viruses) drug called valganciclovir to help researchers understand the side effects of the two drugs when given together and find out whether this treatment can help reduce symptoms and the size of the subject's cancer.
Eligibility Criteria
- Must be at least 18 years old Must have diagnosis of Epstein-Barr Virus-Associated Lymphoid Cancer Cannot have uncontrolled bacterial, viral, or fungal infection(s), or hepatitis B or C Females cannot be pregnant or currently breast-feeding
RESEARCH. INNOVATION. DISCOVERY.